Yamaguchi Ryushiro, Nakagawa Yuji, Sato Munekatsu, Ono Atsushi
Dept. of Surgery, and *2Gastroenterological Surgery, Mito Chuo Hospital.
Gan To Kagaku Ryoho. 2014 Sep;41(9):1183-5.
Retroperitoneal dedifferentiated liposarcoma is associated with a poor prognosis, and the efficacy of chemotherapy in such cases is controversial. We report a case of long -term survival in a patient with dedifferentiated liposarcoma treated with bevacizumab after repeated local recurrences. A 65-year-old man complained of abdominal pain. Abdominal computed tomography (CT) showed a well-enhanced retroperitoneal tumor. The tumor was resected together with the right kidney and adrenal gland. On the basis of histopathological findings, the tumor was diagnosed as a dedifferentiated liposarcoma adenocarcinoma. Eleven months later, local recurrence was diagnosed and the tumor was resected. Thereafter, repeated local recurrences were diagnosed, and repeated tumor resections were performed. Local recurrence and distant metastasis in the axilla and scapula soft tissue was detected 5.9 years after the initial operation. Bevacizumab therapy was initiated, and the tumor markedly reduced in size. Bevacizumab treatment has been continued for 6.7 years after the initial operation, with no tumor recurrence or metastasis.
腹膜后去分化脂肪肉瘤预后较差，化疗对此类病例的疗效存在争议。我们报告一例去分化脂肪肉瘤患者在反复局部复发后接受贝伐单抗治疗获得长期生存的病例。一名65岁男性主诉腹痛。腹部计算机断层扫描（CT）显示腹膜后肿瘤强化明显。该肿瘤与右肾及肾上腺一并切除。根据组织病理学检查结果，肿瘤被诊断为去分化脂肪肉瘤腺癌。11个月后，诊断为局部复发并进行了肿瘤切除。此后，多次诊断为局部复发，并进行了多次肿瘤切除。初次手术后5.9年检测到腋窝和肩胛骨软组织出现局部复发和远处转移。开始使用贝伐单抗治疗，肿瘤大小明显缩小。初次手术后贝伐单抗治疗已持续6.7年，无肿瘤复发或转移。
